News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,252 Results
Type
Article (1560)
Company Profile (5)
Press Release (7686)
Section
Business (4044)
Career Advice (10)
Deals (527)
Drug Delivery (7)
Drug Development (1717)
Employer Resources (5)
FDA (308)
Job Trends (303)
News (6095)
Policy (556)
Tag
2027 BioCapital Standard (1)
Academia (22)
Accelerated approval (3)
ADA (1)
Adcomms (5)
Allergies (2)
Alliances (1028)
ALS (3)
Alzheimer's disease (21)
Antibody-drug conjugate (ADC) (20)
Approvals (287)
Artificial intelligence (14)
ASCO (3)
Autoimmune disease (15)
Bankruptcy (5)
Best Places to Work (154)
BIO (1)
BIOSECURE Act (1)
BioSpace Insights (5)
Biotechnology (3)
Breast cancer (4)
Cancer (121)
Cardiovascular disease (16)
Career advice (12)
CAR-T (1)
CDC (11)
Cell therapy (10)
Clinical research (1450)
Collaboration (60)
Company closure (3)
Compensation (6)
Complete response letters (5)
COVID-19 (120)
CRISPR (3)
C-suite (58)
Cystic fibrosis (1)
Data (86)
Denatured (3)
Depression (2)
Dermatology (2)
Diabetes (1)
Diagnostics (28)
Digital health (2)
Diversity, equity & inclusion (2)
Drug discovery (7)
Drug pricing (14)
Duchenne muscular dystrophy (6)
Earnings (1104)
Editorial (9)
Employer branding (2)
Employer resources (5)
Events (778)
Executive appointments (43)
FDA (338)
Frontotemporal dementia (3)
Funding (31)
Gene editing (5)
Generative AI (1)
Gene therapy (11)
GLP-1 (19)
Government (94)
Guidances (2)
Healthcare (194)
Hematology (1)
HIV (21)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (35)
Immuno-oncology (5)
Indications (5)
Infectious disease (189)
Inflammatory bowel disease (2)
Inflation Reduction Act (2)
Influenza (4)
Intellectual property (4)
IPO (132)
IRA (3)
Job creations (148)
Job search strategy (9)
JPM (7)
Labor market (5)
Layoffs (30)
Leadership (3)
Legal (152)
Liver cancer (2)
Longevity (1)
Lung cancer (20)
Lymphoma (3)
Machine learning (1)
Management (2)
Manufacturing (21)
MASH (8)
Medical device (16)
Medtech (17)
Mergers & acquisitions (399)
Metabolic disorders (27)
mRNA (18)
Multiple sclerosis (1)
Neurodegenerative disease (21)
Neuropsychiatric disorders (4)
Neuroscience (49)
Neurotech (1)
NextGen: Class of 2026 (77)
Non-profit (31)
Now hiring (1)
Obesity (17)
Opinion (13)
Ovarian cancer (10)
Pain (1)
Pancreatic cancer (13)
Parkinson's disease (1)
Partnered (1)
Patents (12)
Patient recruitment (6)
People (1416)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase 1 (369)
Phase 2 (582)
Phase 3 (592)
Pipeline (182)
Policy (29)
Postmarket research (98)
Preclinical (111)
Prostate cancer (6)
Psychedelics (3)
Radiopharmaceuticals (4)
Rare diseases (37)
Real estate (76)
Recruiting (1)
Regulatory (444)
Reports (2)
Research institute (30)
Resumes & cover letters (1)
RNA editing (2)
RSV (32)
Schizophrenia (1)
Series A (5)
Series B (2)
Sickle cell disease (4)
Special edition (6)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (109)
Stomach cancer (5)
Supply chain (2)
Tariffs (6)
The Weekly (16)
Vaccines (123)
Venture capital (14)
Weight loss (11)
Date
Today (1)
Last 7 days (4)
Last 30 days (32)
Last 365 days (465)
2026 (299)
2025 (462)
2024 (495)
2023 (532)
2022 (723)
2021 (606)
2020 (516)
2019 (408)
2018 (330)
2017 (398)
2016 (429)
2015 (658)
2014 (462)
2013 (384)
2012 (337)
2011 (394)
2010 (385)
Location
Africa (36)
Arizona (1)
Asia (596)
Australia (173)
California (145)
Canada (53)
China (35)
Colorado (1)
Connecticut (2)
Delaware (2)
Europe (3232)
Florida (17)
Georgia (9)
Illinois (33)
Indiana (3)
Japan (3)
Maryland (8)
Massachusetts (151)
Nevada (1)
New Hampshire (5)
New Jersey (50)
New York (16)
North Carolina (10)
Northern California (71)
Oklahoma (1)
Pennsylvania (36)
Puerto Rico (1)
South America (22)
Southern California (53)
Texas (52)
United States (507)
Utah (4)
Virginia (2)
Washington D.C. (3)
Washington State (7)
Wisconsin (1)
9,252 Results for "gsk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer assets in late-stage development.
July 23, 2026
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
GSK abandons Alector after back-to-back neuro stumbles
GSK and Alector first partnered in 2021 to advance two antibodies for neurodegenerative diseases. Both assets have since failed to show significant clinical benefit.
July 9, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the first quarter, emerging as the pharma’s top-selling product.
April 29, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK shares rise as $2.5B cost-cutting plan unveiled
As GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.
July 28, 2026
·
4 min read
·
Gabrielle Masson
Approvals
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.
June 18, 2026
·
2 min read
·
Tristan Manalac
Ovarian cancer
4 ovarian cancer candidates to watch: GSK, Allarity and more
Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.
June 29, 2026
·
6 min read
·
Brianna Abbott
Business
GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 fail
Camlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.
July 17, 2026
·
1 min read
·
Tristan Manalac
Antibody-drug conjugates
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
July 10, 2026
·
1 min read
·
Gabrielle Masson
Mergers & acquisitions
GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year
Nuvalent Bio is GSK’s third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for 35Pharma.
June 9, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.
June 10, 2026
·
2 min read
·
Jef Akst
1 of 926
Next
